Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Pfizer begins study of oral drug for prevention of COVID-19
Pfizer begins study of oral drug for prevention of COVID-19
Sept 27 (Reuters) - Pfizer Inc (PFE.
The FDA accelerated drug approval program: benefits and limitations
The FDA accelerated drug approval program: benefits and limitations
The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious dis...
FDA approves ready-to-use norepinephrine injections for severe hypertension
FDA approves ready-to-use norepinephrine injections for severe hypertension
Baxter International has received FDA approval for its premixed doses of Norepinephrine Bitartrate in 5% Dextrose Injection, a ready-to-use treatment for patients with severe, acute hypertension.
Alrizomadlin Lands FDA Fast Track Designation for Melanoma
Alrizomadlin Lands FDA Fast Track Designation for Melanoma
Alrizomadlin, a MDM2-p53 inhibitor has been granted a fast track designation by the FDA for the treatment of relapsed/refractory unresectable or metastatic melanoma who are relapsed or refractory to p...
AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity
AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity
AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the proprietary self-amplifying RNA (saRNA) therapeutics platform de...
CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors
CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors
PHILADELPHIA, Sept.
SAGE-718 on FDA Fast Track as Potential Huntington’s Therapy
SAGE-718 on FDA Fast Track as Potential Huntington’s Therapy
The U.
FDA Approves Opzelura as Treatment for Atopic Dermatitis
FDA Approves Opzelura as Treatment for Atopic Dermatitis
In clinical trials, the majority of patients with atopic dermatitis treated with ruxolitinib had clear or almost clear skin.
Micro-robots propelled by air bubbles and ultrasound
Micro-robots propelled by air bubbles and ultrasound
Some engineers find inspiration in the mechanics of bird flight and the architecture of bee nests.
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
Daix (France), Long Island City (New York, United States), September 21, 2021 – Inventiva (Euronext Paris and Nasdaq.
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study Evaluating the Combination of ZEN-3694 and Enzalutamide in mCRPC Patients Who Responded Poorly to Prior Abiraterone
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study Evaluating the Combination of ZEN-3694 and Enzalutamide in mCRPC Patients Who Responded Poorly to Prior Abiraterone
CALGARY, Alberta, Sept.
Pfizer and BioNTech report positive Covid-19 vaccine trial data in children
Pfizer and BioNTech report positive Covid-19 vaccine trial data in children
The vaccine demonstrated a favourable safety profile and was well-tolerated in children aged five to 11 years.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand